Skip to content
DataLookout
Menu

GPNMB-PERIO StNCT07475013

Effects of Non-Surgical Periodontal Treatment on Inflammatory and Bone Markers in Periodontitis Patients

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reopened Show 4 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Primary completion pushed from Sep 1, 2026 to Feb 1, 2027
    • Study completion pushed from Dec 1, 2026 to Apr 1, 2027
    • Site details revised
  2. Minor Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Gingival Crevicular Fluid (GCF) Glycoprotein Non-Metastatic B (GPNMB) Concentration
Timeframe: Baseline, 6 weeks, and 3 months post-treatment.
Change in Serum Glycoprotein Non-Metastatic B (GPNMB) Concentration
Timeframe: Baseline, 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Crevicular Fluid (GCF) Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Concentration
Timeframe: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Serum Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Concentration
Timeframe: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Crevicular Fluid (GCF) Osteoprotegerin (OPG) Concentration
Timeframe: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Serum Osteoprotegerin (OPG) Concentration
Timeframe: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Gingival Crevicular Fluid (GCF) Transforming Growth Factor beta 1 (TGF-β1) Concentration
Timeframe: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.
Change in Serum Transforming Growth Factor beta 1 (TGF-β1) Concentration
Timeframe: Baseline (before treatment), 6 weeks post-treatment, and 3 months post-treatment.

Secondary (4)

Change in Probing Pocket Depth (PPD)
Change in Clinical Attachment Loss (CAL)
Change in Plaque Index (PI)
Change in Gingival Index (GI)

Arms and interventions

Periodontitis GroupExperimental

Participants with Stage III Grade B/C periodontitis. At baseline, clinical periodontal measurements are recorded, and serum and gingival crevicular fluid samples are collected. All participants receive non-surgical periodontal therapy consisting of Scaling and Root Planing (SRP). Follow-up visits are conducted at 6 weeks and 3 months post-treatment for repeated clinical assessments and sample collection to evaluate changes in biochemical markers (GPNMB, TGF-β1, RANKL, and OPG).

Healthy Control GroupNo intervention

Periodontally healthy individuals. Participants undergo a single clinical periodontal examination and provide serum and gingival crevicular fluid samples at the baseline visit. This group serves as a reference for baseline biochemical marker levels. No therapeutic intervention is performed.

Procedures: Scaling and Root Planing (SRP)

Sites

1 site in 1 country

  • Sağlık Bilimleri Üniversitesi Gülhane Diş Hekimliği FakültesiAnkara, Turkey (Türkiye)